Evidence map›Paper›PMID 21196322›Full record

ReviewFrontiers in bioscience (Elite edition)2011

MYCN, neuroblastoma and focal adhesion kinase (FAK).

Elizabeth A Beierle

Open access · bronzeAbstract readReview
In one paragraph

Review in Frontiers in bioscience (Elite edition), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 2 countries.

Elizabeth A BeierleUniversity of Alabama, Birmingham, Birmingham, AL 35233, USA. elizabeth.beierle@chsys.org
University of Alabama at Birmingham · US

Funding

Focal Adhesion Kinase (FAK) in Human NeuroblastomaK08CA118178 · NCI · UNIVERSITY OF FLORIDA · PI BEIERLE, ELIZABETH A. · 2007 to 2011
$672k
NCI NIH HHS K08 CA118178
6 · The paper itself

Abstract

Neuroblastoma is the most common extracranial solid tumor of childhood. This tumor is characterized by poor survival, especially when it features amplification of the MYCN oncogene. The ability for human cancers to propagate is marked by their ability to invade and metastasize to distant sites. Focal adhesion kinase (FAK) is a key tyrosine kinase involved in the survival and metastasis of a number of human tumor types. We have shown that FAK is present in human neuroblastoma and that its expression in neuroblastoma is related to the MYCN oncogene. We have also demonstrated that inhibition of FAK in neuroblastoma leads to decreased tumor cell survival. The current review addresses the relationship between the MYCN oncogene, focal adhesion kinase and neuroblastoma.

Indexed as

Cell AdhesionFocal Adhesion Protein-Tyrosine KinasesGene Expression Regulation, NeoplasticHumansNeuroblastomaN-Myc Proto-Oncogene ProteinNuclear ProteinsOncogene ProteinsFocal Adhesion Protein-Tyrosine KinasesMYCN protein, humanN-Myc Proto-Oncogene ProteinNuclear ProteinsOncogene Proteins

Identifiers

PMID21196322
PMCPMC3171213
OpenAlexW1446039215

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.